Acute coronary syndrome

News

BMS and J&J call time on oral anticoagulant milvexian in acute coronary syndrome, but are still running trials in atrial fibrillation and stroke.

Oncology

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.